Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Issue 3 (17th February 2022)

• Record Type: Journal Article
• Authors: Ghazi, Lama; Li, Fan; Chen, Xinyuan; Simonov, Michael; Yamamoto, Yu; Biswas, Aditya; Hanna, Jonathan; Shah, Tayyab; Townsend, Raymond; Peixoto, Aldo; Wilson, F. Perry
• Is Part Of: Journal of clinical hypertension. Volume 24:Issue 3(2022)
• Page Start: 339
• Page End: 349
• Publication Date: 2022-02-17
• Subjects: antihypertensive therapy -- blood pressure response -- electronic health records -- hypertension -- inpatient; Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.14431
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract: Severe hypertension (HTN) that develops during hospitalization is more common than admission for HTN; however, it is poorly studied, and treatment guidelines are lacking. Our goal is to characterize hospitalized patients who develop severe HTN and assess blood pressure (BP) response to treatment. This is a multi‐hospital retrospective cohort study of adults admitted for reasons other than HTN who developed severe HTN. The authors defined severe inpatient HTN as the first documented BP elevation (systolic BP > 180 or diastolic BP > 110) at least 1 hour after admission. Treatment was defined as receiving antihypertensives (intravenous [IV] or oral) within 6h of BP elevation. As a measure of possible overtreatment, the authors studied the association between treatment and time to mean arterial pressure (MAP) drop ≥ 30% using the Cox proportional hazards model. Among 224 265 hospitalized adults, 10% developed severe HTN of which 40% were treated. Compared to patients who did not develop severe HTN, those who did were older, more commonly women and black, and had more comorbidities. Incident MAP drop ≥ 30% among treated and untreated patients with severe HTN was 2.2 versus 5.7/1000 person‐hours. After adjustment, treated versus. untreated patients had lower rates of MAP drop ≥ 30% (hazard rate [HR]: 0.9 [0.8, 0.99]). However, those receiving only IV treatment versus untreated had greater rates of MAP drop ≥ 30% (1.4 [1.2, 1.7]). Overall, the authors found that clinically significant MAP drop is observed among inpatients with severe HTN irrespective of treatment, with greater rates observed among patients treated only with IV antihypertensives. Further research is needed to phenotype inpatients with severe HTN.